13F Holdings
中文EN

SCNX Scienture Holdings, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1382574 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY127.4%
TTM net income YoY-96.3%
TTM EPS YoY144.2%
Revenue 3-yr CAGR-24.9%
Net income 3-yr CAGR—

Margins

Gross margin78.5%
Operating margin-2,788.5%
Net margin-2,715.9%
FCF margin—
EBITDA margin-2,662.9%

Returns

ROE-57.1%
ROA-47.1%
ROIC (approx.)-47.3%
Asset turnover0.02x

Leverage & solvency

Liabilities / assets32.6%
Debt / equity0.00x
Current ratio1.10x
Interest coverage-25.26x

Cash quality & payout

Operating cash flow / net income0.36x
Accruals ratio-30.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$431,609$136,643$1.36M$10.25M$9.89M
Cost of revenue$100,127$130,638$1.31M$4.73M$5.14M
Gross profit$331,482$6,005$49,030$5.52M$4.75M
R&D expense$1.96M$2.24M———
SG&A expense$7.93M$6.68M$1.34M$1.69M$1.90M
Operating income-$42.59M-$14.70M-$4.40M-$2.92M-$5.29M
Interest expense$4.08M$1.34M$1.14M$336,206$23,590
Pretax income-$43.51M-$18.78M-$8.48M——
Income tax-$1.99M-$534,396———
Net income-$41.51M$9.07M-$17.84M-$3.47M-$5.32M
EBITDA-$42.10M-$14.70M-$4.38M-$2.90M-$5.28M
EPS (basic)-2.702.69-23.35-6.15-0.65
EPS (diluted)-2.702.48-23.35-6.13-0.65
Weighted avg. shares (diluted)15.35M3.65M2.38M566,6098.14M
Banking
Deposits$1.18M————
Balance sheet
Cash & equivalents$6.66M$308,096$314$1.09M$3.12M
Receivables$731,328$11,106$8,492$629,921$978,973
Inventory$213,408—$968$65,523$56,279
Current assets$7.92M$6.31M$2.75M$2.09M$4.37M
PP&E, net$15,500$17,500$7,500$65,214$98,751
Goodwill—$21.37M—$0$0
Intangibles$70.97M$76.40M$8.96M——
Total assets$84.18M$104.85M$12.53M$3.71M$5.77M
Current liabilities$2.74M$7.91M$11.56M$2.15M$926,026
Long-term debt—$2.90M———
Total debt—$2.90M———
Total liabilities$14.06M$25.78M$11.99M$3.37M$2.00M
Shareholders' equity$70.12M$79.07M$542,353$763,136$3.77M
Net debt—$2.59M———
Shares outstanding1.63M8.75M905,008626,2478.17M
Cash flow statement
Operating cash flow-$13.38M-$14.27M-$2.23M-$199,020-$2.57M
Capital expenditure—$12,000——$22,596
Free cash flow—-$14.28M——-$2.59M
Investing cash flow—$27.55M-$275,717$749-$22,596
Financing cash flow$19.73M-$12.98M$1.41M$239,829-$208,178
Depreciation & amortization$491,781$2,000$19,375$13,486$7,351
Stock-based compensation$2.07M$25,584$29,738$79,163$64,167
Dividends paid—$14.86M———

Free plan shows the latest 5 periods; Pro shows all 13 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.